Floatz logo

cb-012

Acute Myeloid Leukemia Refractory

Caribou Biosciences, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Acute Myeloid Leukemia Refractory cohort.

Asset / SponsorPhaseRating
np137
Centre Leon Berard
Phase 1/2CC
Ucb-Nk Cells
Radboud University Medical Center
Phase 1/2CC
ab8939
AB Science
Phase 1/2CC
Anti-Siglec-6 Car-T Cell Therapy
Xuzhou Medical University
Phase 1/2CC
Apl-4098
Apollo Therapeutics Ltd
Phase 1CC

View all 9 →

Same molecule, other indications

cb-012 is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →